National Institute for Health and Clinical Excellence (NICE)
NICE draft guidance addresses the continuing debate about the best approach to the diagnosis and management of ME/CFS
NICE yesterday (10 November 2020) published its draft updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).
The draft guideline recognises that ME/CFS, which is estimated to affect over 250,000 people in England and Wales, is a complex, multi-system, chronic medical condition where there is no ‘one size fits all’ approach to managing symptoms. It stresses the need for a tailored, individualised approach to care that allows joint decision making and informed choice.
Because of the harms reported by people with ME/CFS, as well as the committee’s own experience of the effects when people exceed their energy limits, the draft guideline says that any programme based on fixed incremental increases in physical activity or exercise, for example graded exercise therapy (GET) should not be offered for the treatment of ME/CFS.
Instead, it highlights the importance of ensuring that people remain in their ‘energy envelope’ when undertaking activity of any kind and recommends that a physical activity programme, in particular, should only be considered for people with ME/CFS in specific circumstances.
The draft guideline also emphasises that cognitive behavioural therapy (CBT) it is not a treatment or cure for ME/CFS. However, as a supportive therapy which aims to improve wellbeing and quality of life, the draft guideline says CBT may be useful in supporting people who live with ME/CFS to manage their symptoms.
Paul Chrisp, director of the Centre for Guidelines at NICE, yesterday said:
“ME/CFS can cause profound, long-term illness and disability, and much of the distress surrounding it is caused by difficulties in recognising, acknowledging and accepting the condition and its impact. This has been compounded further by a lack of effective treatments, wide variation in access to services, and by controversy over the use of graded exercise therapy and CBT that has served only to alienate many people with ME/CFS and in some cases undermine the confidence of those caring for them.
“The recommendations in this draft guideline have been developed by an independent committee that was guided not just by the clinical evidence, but also by the experience and testimony of people with ME/CFS. The result is a guideline that will provide much needed clarity, set new standards for health professionals and ensure that people with ME/CFS have access to the right care and support.”
Adam Lowe, a lay member of the guideline committee, yesterday said:
“ME/CFS patients have been voicing their concerns about graded exercise therapy for a long time, and the evidence presented to the committee supported these concerns.
“One of the key points in the draft guideline is that exercise is not a treatment or cure for ME/CFS and should not be presumed to be safe for those with this disabling and often neglected illness. The approach it recommends is a pragmatic one which allows patients to self-manage themselves, within their daily limits, while using readily available interventions to address the most serious of their symptoms first.”
The draft guideline recommends reducing the time from 4 months to 3 months that a person needs to have persistent symptoms before a diagnosis of ME/CFS can be confirmed. It says that people should then be directed to a specialist team (in the case of children this should be a paediatric specialist team) experienced in the management of ME/CFS to confirm their diagnosis and develop a personalised management plan. This will enable people to access care earlier and could potentially improve longer term outcomes.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer26/02/2021 16:15:00
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition.
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE25/02/2021 15:20:00
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria25/02/2021 14:15:00
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
A new instrument for consideration of a broader range of benefits for people, their families and carers18/02/2021 14:15:00
Blog posted by: Bhash Naidoo Senior Technical Adviser – Health Economics at NICE, 17 February 2021.
Skin cancer drug recommended for routine NHS use15/02/2021 09:15:00
An appeal period has now opened until 26 February 2021.
NICE recommends treatment options for severe pregnancy sickness in new draft guidance11/02/2021 15:15:00
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks
NICE’s processes of technology evaluation - presenting a case for change04/02/2021 15:20:00
NICE has today (4 February 2021) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies
Thousands of lung cancer patients to benefit from life-extending treatment04/02/2021 12:10:00
A potentially life-extending treatment for some people with non-squamous, non-small-cell lung cancer (NSCLC) will now be available on the NHS following its approval by NICE in draft guidance published today